Karolinska Development invests SEK 7.5 million to support BOOST Pharma’s continued development of BT-101 towards Phase 3

Stockholm, Sweden – October 28, 2025. Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that it has exercised its pro rata participation of SEK 7.5 million in BOOST Pharma’s latest financing. In total, BOOST Pharma’s financing, structured as a convertible loan, brings SEK 15 million to the company. The investment supports the continued preparation for Phase III clinical development of BT-101, a pioneering stem cell-based therapy for osteogenesis imperfecta (OI), also known as brittle bone disease. 

BOOST Pharma, a clinical-stage biopharmaceutical company, is advancing BT-101 as a novel mesenchymal stem cell therapy for infants born with osteogenesis imperfecta (OI) , a condition characterized by fragile bones, frequent fractures and bone deformity. The treatment is designed to reduce fracture frequency in affected pediatric patients providing a possible treatment advantage in the early years of life, when most fractures occur. With the proceeds from this financing, BOOST Pharma aims to accelerate the ongoing clinical program and move closer to providing the first disease-modifying therapy for OI.